FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387395662> ?p ?o ?g. }

• W4387395662 abstract "Abstract Background: The role of inflammation in the aetiology of schizophrenia has gained wide attention and research on the association shows an exponential growth in the last 15 years. Autoimmune diseases and severe infections are risk factors for the later development of schizophrenia, elevated inflammatory markers in childhood or adolescence are associated with a greater risk of schizophrenia in adulthood, individuals with schizophrenia have increased levels of pro-inflammatory cytokines compared to healthy controls, and autoimmune diseases are overrepresented in schizophrenia. However, treatments with anti-inflammatory agents are so far of doubtful clinical relevance. The primary objective of this study is to test whether the monoclonal antibody rituximab, directed against the B-cell antigen CD20 ameliorates psychotic symptoms in adults with schizophrenia or schizoaffective disorder and to examine potential mechanisms. A secondary objective is to examine characteristics of inflammation-associated psychosis and to identify pre-treatment biochemical characteristics of rituximab responders. A third objective is to interview a subset of patients and informants on their experiences of the trial to obtain insights that rating scales may not capture. Methods: A proof-of-concept study employing a randomised, parallel-group, double-blind, placebo-controlled design testing the effect of B-cell depletion in patients with psychosis. 120 participants with a diagnosis of schizophrenia spectrum disorders (SSD) (ICD-10 codes F20, F25) will receive either one intravenous infusion of rituximab (1000 mg) or saline. Psychiatric measures and blood samples will be collected at baseline, week 12, and week 24 post-infusion. Brief assessments will also be made in weeks 2 and 7. Neuroimaging and lumbar puncture, both optional, will be performed at baseline and endpoints. Approximately 40 of the patients and their informants will be interviewed for qualitative analyses on the perceived changes in well-being and emotional qualities, in addition to their views on the research. Discussion: This is the first RCT investigating add-on treatment with rituximab in unselected SSD patients. If the treatment is helpful, it may transform the treatment of patients with psychotic disorders. It may also heighten the awareness of immune-psychiatric disorders and reduce stigma. Trial registration: NCT05622201, EudraCT-nr 2022-000220-37 version 2.1. registered 14 th of October 2022." @default.
• W4387395662 created "2023-10-07" @default.
• W4387395662 creator A5000300261 @default.
• W4387395662 creator A5002342124 @default.
• W4387395662 creator A5005439924 @default.
• W4387395662 creator A5006420656 @default.
• W4387395662 creator A5029574907 @default.
• W4387395662 creator A5031713260 @default.
• W4387395662 creator A5032310388 @default.
• W4387395662 creator A5037225663 @default.
• W4387395662 creator A5040096761 @default.
• W4387395662 creator A5043864006 @default.
• W4387395662 creator A5044888240 @default.
• W4387395662 creator A5055211311 @default.
• W4387395662 creator A5088234582 @default.
• W4387395662 date "2023-10-06" @default.
• W4387395662 modified "2023-10-07" @default.
• W4387395662 title "Study protocol for A randomized controlled trial with Rituximab for Psychotic disorder in adults (RCT-Rits)" @default.
• W4387395662 cites W1992857340 @default.
• W4387395662 cites W1999110121 @default.
• W4387395662 cites W2013122153 @default.
• W4387395662 cites W2040532973 @default.
• W4387395662 cites W2042755650 @default.
• W4387395662 cites W2075199575 @default.
• W4387395662 cites W2078785782 @default.
• W4387395662 cites W2101357408 @default.
• W4387395662 cites W2102181001 @default.
• W4387395662 cites W2111517139 @default.
• W4387395662 cites W2121637331 @default.
• W4387395662 cites W2134549690 @default.
• W4387395662 cites W2140606211 @default.
• W4387395662 cites W2162253908 @default.
• W4387395662 cites W2165608395 @default.
• W4387395662 cites W2255138985 @default.
• W4387395662 cites W2333927324 @default.
• W4387395662 cites W2520656017 @default.
• W4387395662 cites W2755088322 @default.
• W4387395662 cites W2766457141 @default.
• W4387395662 cites W2772300842 @default.
• W4387395662 cites W2801180445 @default.
• W4387395662 cites W2807882529 @default.
• W4387395662 cites W2888647009 @default.
• W4387395662 cites W2896834526 @default.
• W4387395662 cites W2900366804 @default.
• W4387395662 cites W2924236163 @default.
• W4387395662 cites W2946688520 @default.
• W4387395662 cites W2958423778 @default.
• W4387395662 cites W2984627042 @default.
• W4387395662 cites W2990532243 @default.
• W4387395662 cites W2990915417 @default.
• W4387395662 cites W3008780596 @default.
• W4387395662 cites W3009315387 @default.
• W4387395662 cites W3013731225 @default.
• W4387395662 cites W3021345946 @default.
• W4387395662 cites W3035856048 @default.
• W4387395662 cites W3082301634 @default.
• W4387395662 cites W3088407417 @default.
• W4387395662 cites W3096307731 @default.
• W4387395662 cites W3122837017 @default.
• W4387395662 cites W3129324699 @default.
• W4387395662 cites W3131715422 @default.
• W4387395662 cites W3134016018 @default.
• W4387395662 cites W3195334679 @default.
• W4387395662 cites W3197710304 @default.
• W4387395662 cites W3214458709 @default.
• W4387395662 cites W3216918706 @default.
• W4387395662 cites W4205337895 @default.
• W4387395662 cites W4220697223 @default.
• W4387395662 cites W4220746180 @default.
• W4387395662 cites W4244847179 @default.
• W4387395662 cites W4247665917 @default.
• W4387395662 cites W4285384973 @default.
• W4387395662 cites W4308485574 @default.
• W4387395662 cites W4311950273 @default.
• W4387395662 cites W4316016059 @default.
• W4387395662 cites W4360843964 @default.
• W4387395662 cites W4380985504 @default.
• W4387395662 doi "https://doi.org/10.21203/rs.3.rs-3377141/v1" @default.
• W4387395662 hasPublicationYear "2023" @default.
• W4387395662 type Work @default.
• W4387395662 citedByCount "0" @default.
• W4387395662 crossrefType "posted-content" @default.
• W4387395662 hasAuthorship W4387395662A5000300261 @default.
• W4387395662 hasAuthorship W4387395662A5002342124 @default.
• W4387395662 hasAuthorship W4387395662A5005439924 @default.
• W4387395662 hasAuthorship W4387395662A5006420656 @default.
• W4387395662 hasAuthorship W4387395662A5029574907 @default.
• W4387395662 hasAuthorship W4387395662A5031713260 @default.
• W4387395662 hasAuthorship W4387395662A5032310388 @default.
• W4387395662 hasAuthorship W4387395662A5037225663 @default.
• W4387395662 hasAuthorship W4387395662A5040096761 @default.
• W4387395662 hasAuthorship W4387395662A5043864006 @default.
• W4387395662 hasAuthorship W4387395662A5044888240 @default.
• W4387395662 hasAuthorship W4387395662A5055211311 @default.
• W4387395662 hasAuthorship W4387395662A5088234582 @default.
• W4387395662 hasBestOaLocation W43873956621 @default.
• W4387395662 hasConcept C118552586 @default.
• W4387395662 hasConcept C126322002 @default.
• W4387395662 hasConcept C142724271 @default.
• W4387395662 hasConcept C15744967 @default.

• next